September 14, 2021

In this installment of The Legal Prescription with Pharmacy Times, Ned Milenkovich, chair of Much’s Health Care group, discusses HR 841 – the Hemp Bill. Ned sets the record straight on the FDA's stance, outlines the importance of regulations and good manufacturing processes, and explains the likely economic impact of the bill.

This article contains material of general interest and should not be construed as legal advice or a legal opinion on any specific facts or circumstances. Under applicable rules of professional conduct, this content may be regarded as attorney advertising.